Biography
- Division:
- Division of Translational and Clinical Sciences – DTCS
- Review Branch:
- Cancer Therapeutics – CTH
- Study Section:
- Drug Discovery and Molecular Pharmacology C – DMPC
Dr. Alireza Alavi received his Ph.D. in cell and molecular biology from the University of Pennsylvania and an MBA from the Wharton School. He completed his post-doctoral training at the Scripps Research Institute, focusing on regulation of cell death during tumor angiogenesis. He transitioned to industry, where he performed preclinical studies on small-molecule regulators of the death receptor pathway and the identification and validation of cell surface receptors amenable to targeting by ADCs. He then transitioned to translational research, developing clinical biomarkers in support of ADC, cancer vaccines, and CAR T-cell therapies. Dr. Alavi has held leadership roles at GlaxoSmithKline Oncology, Autolus Therapeutics, and IO Biotech, where he led cross-functional teams and established translational research laboratories to support exploratory biomarkers in phase I-III clinical trials.
